A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis
Ian Olver, Walter Paska, Alain Depierre et al. · Annals of Oncology · 1996
Cited by 73 works. doi:10.1093/oxfordjournals.annonc.a010798
Authors
- Ian Olver
- Walter Paska
- Alain Depierre
- J. F. Seitz
- David J. Stewart
- Louis Goedhals
- B. McQuade
- James Wilkinson
References
- On the receiving end—patient perception of the side-effects of cancer chemotherapy
- Comparison of the 5-Hydroxytryptamine 3 (Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
- Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.
- Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
- Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting
- Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
- Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.
- Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting.
- Quality of life consequences of chemotherapy-induced emesis
- Nausea and Vomiting as Major Complications of Cancer Chemotherapy